SCHEMBL308242

SCHEMBL308242

COC(=O)c1cccc([N+](=O)[O-])c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
ALDH1A1 P00352 9/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HSD17B10 Q99714 2/20 0.50
KMT2A Q03164 2/20 0.50
CFTR P13569 1/20 0.50
MEN1 O00255 1/20 0.50
CTSD P07339 1/20 0.49
MAPT P10636 4/20 0.48
MAPK1 P28482 3/20 0.48
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
ABCC4 O15439 1/20 0.48
PLIN1 O60240 1/20 0.48
CACNA1F O60840 1/20 0.48
GMNN O75496 1/20 0.48
KCNK2 O95069 1/20 0.48
ABCB11 O95342 1/20 0.48
GSR P00390 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14933431 0.83 TSHR (0.56) TSHRALDH1A1SMN1; SMN2HSD17B10KMT2A
SCHEMBL29959661 0.83 TSHR (0.70) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL307312 0.83 TSHR (0.70) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL4728649 0.83 ALDH1A1 (0.54) TSHRALDH1A1SMN1; SMN2HSD17B10KMT2A
SCHEMBL195311 0.83 ALDH1A1 (0.62) TSHRALDH1A1SMN1; SMN2HSD17B10KMT2A
SCHEMBL50994 0.82 TSHR (0.54) TSHRALDH1A1SMN1; SMN2HSD17B10KMT2A
SCHEMBL7369896 0.82 TSHR (0.54) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL31258847 0.82 GPR35 (0.58) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL391265 0.82 GPR35 (0.58) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
Hydrochloric Acid SCHEMBL30013910 0.81 ALDH1A1 (0.61) TSHRALDH1A1SMN1; SMN2HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111253271-B Method for preparing 2-amino-3-nitrobenzoic acid methyl ester 浙江聚贤医药科技有限公司 2023-02-28 CN claimed
CN-111253271-A Method for preparing 2-amino-3-nitrobenzoic acid methyl ester 浙江聚贤医药科技有限公司 2020-06-09 CN claimed
WO-2008012852-A1 INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS S.I.M.S. S.r.l. - SOCIETÀ ITALIANA MEDICINALI SCANDICCI (IT) 2008-01-31 WO claimed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-08-26 US disclosed
CN-116143628-B Preparation method of nitrobenzamide 南通泰禾化工股份有限公司 2025-03-25 CN disclosed
WO-2025059074-A1 BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2025-03-20 WO disclosed
CN-114835621-B Imine IDO inhibitor and preparation and application thereof 江苏天士力帝益药业有限公司 2025-03-18 CN disclosed
EP-4219460-B1 TRANSGLUTAMINASE 2 (TG2) INHIBITORS SITARI PHARMA INC (US) 2025-02-26 EP disclosed
US-12234220-B2 Immunomodulatory compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-02-25 US disclosed
CN-1195985-A Benzimidazole compounds UNIV NEWCASTLE VENTURES LTD (GB) 1998-10-14 CN disclosed
EP-0841924-A1 BENZIMIDAZOLE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1998-05-20 EP disclosed
US-5635525-A DIAGNOSTICS HOECHST AKTIENGESELLSCHAFT (DE) 1997-06-03 US disclosed
WO-1997004771-A1 BENZIMIDAZOLE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1997-02-13 WO disclosed
US-5444068-A Imidazopyridine derivatives as angiotensin II receptor antagonists, pharmaceuticals, and treatment of hypertension therewith HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-22 US disclosed
CN-1070646-A Imidazo-fused iso and heterocycle, their preparation method contains their composition and their application HOECHST AG (DE) 1993-04-07 CN disclosed
EP-0147211-B1 4H-3,1-BENZOXAZIN-4-ONES AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION SYNTEX (U.S.A.) INC. (US) 1990-09-12 EP disclosed
US-4657893-A ANTIINFLAMMATORY AGENTS SYNTEX (U.S.A.) INC. (US) 1987-04-14 US disclosed
EP-0147211-A2 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation SYNTEX (U.S.A.) INC. (US) 1985-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 TSHR 3250/4885ALDH1A1 361/4885SMN1; SMN2 4790/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B TSHR 182/4885ALDH1A1 877/4885SMN1; SMN2 3935/4885
US-12234220-B2 Immunomodulatory compounds CRBN, CD47, CD58 TSHR 4538/4885ALDH1A1 3939/4885SMN1; SMN2 880/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 TSHR 2086/4885ALDH1A1 790/4885SMN1; SMN2 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.